Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
Key facts
- Where
- Charleston, Dallas, Houston, and Livonia, United StatesSee the 4 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT07623668, who can take part
Where in United States
- Medical University of South Carolina, Storm Eye InstituteCharleston, United StatesTaking people
- UT Southwestern Medical Center (Ophthalmology CRU)Dallas, United StatesTaking people
- Neuro-Eye Clinical TrialsHouston, United StatesTaking people
- Kahana Oculoplastic and Orbital SurgeryLivonia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oculis
- Trial code
- NCT07623668
- Record updated
- 14 August 2026
- Original description
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).Read full original descriptionShow less
A Randomized, Double-masked, Placebo-controlled Study Assessing the Efficacy and Safety of Privosegtor (OCS-05) in Patients With Optic Neuritis (ON)
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).
Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).
Inclusion: Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss; Onset of visual loss symptoms in the previous 12 days before first administration of study treatment.
Exclusion: Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety.